Galectin Therapeutics (GALT) Interest & Investment Income (2010 - 2026)
Galectin Therapeutics' (GALT) quarterly Interest & Investment Income came in at $36000.0 in Q1 2026, up 2.86% year-on-year from $35000.0 in Q1 2025, and up 44.0% quarter-over-quarter from $25000.0 in Q4 2025.
Galectin Therapeutics (GALT) Interest & Investment Income (2010 - 2026) Analysis & Trends
Galectin Therapeutics' Interest & Investment Income history runs 17 years deep, the most recent figure standing at $36000.0 for Q1 2026.
- On a quarterly basis, Interest & Investment Income rose 2.86% year-over-year to $36000.0 in Q1 2026; TTM through Mar 2026 was $126000.0, a 56.85% decrease from a year earlier, with the FY2025 full-year figure at $126000.0, down 62.72% from the prior year.
- Interest & Investment Income rose to $36000.0 in Q1 2026 per GALT's latest filing, from $25000.0 in the prior quarter.
- Across five years, Interest & Investment Income topped out at $93000.0 in Q3 2024 and bottomed at $1000.0 in Q1 2022.
- The 5-year median for Interest & Investment Income is $39000.0 (2025), against an average of $45882.4.
- Across the five-year window, Interest & Investment Income surged 4300.0% in 2023 and sank 70.24% in 2025, its largest moves.
- Year by year, Interest & Investment Income stood at $30000.0 in 2022, then jumped by 146.67% to $74000.0 in 2023, then climbed by 13.51% to $84000.0 in 2024, then sank by 70.24% to $25000.0 in 2025, then surged by 44.0% to $36000.0 in 2026.
- Per Business Quant, the three latest GALT Interest & Investment Income figures stand at $36000.0 (Q1 2026), $25000.0 (Q4 2025), and $39000.0 (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 27.66 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 114.80 Mn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -65.80 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 48.00 Mn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 19.51 Mn |
| 10 | Galectin Therapeutics | 225.30 Mn | 225.30 Mn | - | 36,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 36,000.00 |
| Dec 31, 2025 | 25,000.00 |
| Sep 30, 2025 | 39,000.00 |
| Jun 30, 2025 | 26,000.00 |
| Mar 31, 2025 | 35,000.00 |
| Dec 31, 2024 | 84,000.00 |
| Sep 30, 2024 | 93,000.00 |
| Jun 30, 2024 | 80,000.00 |
| Mar 31, 2024 | 80,000.00 |
| Dec 31, 2023 | 74,000.00 |
| Sep 30, 2023 | 62,000.00 |
| Jun 30, 2023 | 50,000.00 |
| Mar 31, 2023 | 44,000.00 |
| Dec 31, 2022 | 30,000.00 |
| Sep 30, 2022 | 18,000.00 |
| Jun 30, 2022 | 3,000.00 |
| Mar 31, 2022 | 1,000.00 |
| Sep 30, 2021 | 1,000.00 |
| Jun 30, 2021 | 1,000.00 |
| Mar 31, 2021 | 1,000.00 |